My wholesaler handles DSCSA, what does my independent pharmacy still owe?

The short answer, before anything else: no, your wholesaler’s DSCSA compliance does not discharge your pharmacy’s. The FDA letter that grants the small-dispenser exemption is explicit about who it covers and what it is scoped to, and reading those two sentences closely settles the question. It grants exemptions to “small business dispensers, and, where noted, small business dispensers’ trading partners”, and it applies them to “products they transact with each other.” That is a relief granted to both sides of a transaction pair. It is not a relief that moves from one side to the other.

Does my wholesaler’s DSCSA compliance cover my pharmacy?

No. A wholesale distributor is a separate trading partner with its own set of §582 obligations, and meeting them says nothing about whether the dispenser at the other end of the transaction has met its own. The FDA letter draws that boundary in one sentence: “The exemptions described below do not apply to other requirements in section 582 of the FD&C Act.” Every duty §582 writes against a dispenser, and there are many outside the six lettered obligations of §582(g)(1), ran throughout the exemption window, on the pharmacy, regardless of who it buys from.

The clearest example is verification of suspect product. The exemption removed one narrow slice of it, the §582(d)(4)(A)(ii)(II) and (d)(4)(B)(iii) requirement to verify the product identifier of a designated proportion of suspect or illegitimate product. The very next sentence closes the door: “Small business dispensers are still obligated to meet all other verification requirements of section 582(d)(4) of the FD&C Act.” Those are quarantine, investigation, notification and disposition duties that happen inside your pharmacy, on your shelf, by your staff. No distributor performs them for you.

Which obligations does the exemption give my wholesaler and me jointly?

Four of the six, after FDA rewrote the bullets on 6 August 2026. For §582(g)(1)(A) through (D), the relief is written in the plural and names both parties: “Small business dispensers and their trading partners may continue to rely on current methods.” That phrasing is what makes the arrangement workable in practice. If the exemption applied only to the pharmacy, a wholesaler would still be obliged to send package-level product identifiers in a secure, interoperable, electronic form to a customer with no system able to receive them. The joint grant is what lets the existing method, a portal, an ASN, a PDF, whatever you use today, keep working at both ends until 27 November 2027.

The two bullets that are not jointly worded are the two worth reading twice. On §582(g)(1)(E), gathering transaction information back to the manufacturer, the sentence now reads “If small business dispensers directly transacted the product(s) subject to the request, they may use current methods to respond.” In the superseded 12 July 2024 letter that same “directly transacted” condition sat on the trading partner. It is now a condition on you, and product that reached your shelves through a supplier you did not transact with directly falls outside it. On §582(g)(1)(F), saleable returns, the relief is addressed to “Small business dispensers’ trading partners”, possessive, not conjunctive. That single apostrophe is the one place in the letter where “my wholesaler handles that” is a fair reading of the document.

Read carefully, that is a statement about format, not about responsibility. The exemption for (A) permits you both to “continue to rely on current methods for providing, capturing, and maintaining transaction information and transaction statements.” Capturing and maintaining are still yours. The relief is that they need not be interoperable and electronic yet, not that someone else does them.

Is there an obligation the FDA letter hands to my trading partner alone?

One: saleable returns. For §582(g)(1)(F), the relief sentence changes its subject. Where (A) through (D) each read “small business dispensers and their trading partners”, (F) reads “Small business dispensers’ trading partners may use current methods to accept saleable returns.” The possessive is doing the work. The obligation in (F) falls on “each person accepting a saleable return”, which in the ordinary flow of a pharmacy returning stock is the distributor, not the pharmacy.

It is worth naming precisely because it is the one place where “my wholesaler handles that” is a fair description of what the FDA document says. It is also the narrowest of the six, and it is the only one addressed to the partner alone. Generalising from it is how pharmacies end up assuming the other five moved too.

Which DSCSA obligations stay with my pharmacy whatever my wholesaler provides?

The ones an inspection actually tests, and the 6 August 2026 letter did not hand any of them to your distributor. Obligation (D) is for “systems and processes necessary to promptly respond with the transaction information and transaction statement for a product upon a request by the Secretary, or other appropriate Federal or State official, in the event of a recall or for the purposes of investigating a suspect product or an illegitimate product.” The new letter does extend the (D) relief to your trading partners as well as to you, where the 2024 letter did not, but read what that relief is. It permits both of you to “continue to rely on current methods to respond to requests for such information.” It relaxes the method. The request still arrives at your pharmacy, and a distributor holding the underlying data does not make you able to answer it, that requires knowing who answers, from which system, within what turnaround, and being able to show the person concerned was trained.

Obligation (E) carries an explicit limit, and on 6 August 2026 that limit changed hands. The relief now reads “If small business dispensers directly transacted the product(s) subject to the request, they may use current methods to respond to such requests with their relevant transaction information.” In the 2024 letter the same condition sat on the trading partner; it now sits on you. Either way the practical consequence for an independent is the same and it is the one worth planning around: product that reached your shelves through a secondary supplier, a co-op, or a wholesaler you no longer use is outside that sentence. The gathering duty across all your sources is yours.

And the §582(d)(4) verification duties described above sit alongside them, expressly preserved in both letters. Together these are the written half of DSCSA: the exemption determination, the trading-partner verification log, the suspect-product procedure, the tracing response runbook, the training record. None of them is a data feed, and none of them arrives from a distributor.

Do I have to tell my wholesaler I am relying on the exemption?

Not as a legal requirement, but the FDA suggests it and there is a practical reason to. The letter says: “If a small business dispenser relies on the exemptions outlined here, we recommend communicating such reliance to its trading partners as needed to further facilitate distribution of product without difficulty or delay.” The word is recommend. Note that this is deliberately weaker than the language FDA used for other trading partners in its separate 9 October 2024 letter, and a small-dispenser page that borrows the stronger wording is misquoting the document that governs you.

The practical reason is in the tail of that sentence, “without difficulty or delay.” A distributor whose systems expect full serialized exchange may hold or question an order from a customer it has not been told is exempt. Telling them is about keeping product moving, not about compliance status. Separately, and usefully: nothing goes to the regulator. “Small dispensers and their trading partners who utilize these exemptions do not need to submit any additional information to FDA.” There is no form, no registration and no filing fee.

Does buying from one large wholesaler make my pharmacy exempt?

No, the exemption is a headcount test, and your supplier has no bearing on it. A dispenser qualifies if “the corporate entity that owns the dispenser has a total of 25 or fewer full-time employees licensed as pharmacists or qualified as pharmacy technicians.” Two details in the footnotes decide more cases than the sentence itself: the count is taken across the whole owning corporate entity rather than per store, and it is measured as of a fixed date. That date moved with the extension. Footnote 7 of the 2024 letter read “The total number of employees as of November 27, 2024”; footnote 14 of the 6 August 2026 letter reads “The total number of employees as of November 27, 2026.” The first still governs the window running now. The second governs the extra year, and it has not happened yet, so eligibility for that year is something you can still change by hiring.

Full-time is the IRS definition FDA cites: an employee employed on average at least 30 hours of service per week, or 130 hours per month, for a calendar month. Part-time technicians do not count toward the 25. If your company was over the line on 27 November 2024, you were never on the first track at all, the relief for dispensers with 26 or more full-time employees ran only to 27 November 2025 and has already expired. That letter was not extended: the 6 August 2026 notice says the enhanced requirements “remain in effect and are applicable for all other trading partners who do not meet the definition of a small business dispenser.” Our free checker walks the test in about a minute and stores nothing.

What should I actually ask my wholesaler?

Three questions, in writing, so the answers are part of your record rather than a recollection. First: in what format and through which system will you send transaction information and transaction statements after 27 November 2027, and what must we do to receive it? Second: for how long do you retain the transaction data for products you sold us, and how do we retrieve a specific NDC and lot without calling? Third: what is your process when we report a suspect product back to you?

This page deliberately does not characterise any particular distributor’s DSCSA programme. What a named wholesaler provides varies by company, by contract and by customer tier, and we are not going to describe someone else’s offering without quoting their own published words. What is quotable is the FDA letter, which assigns the duties, and it assigns three of them to you.

FDA just gave me another year, can I wait?

The FDA answered that one directly, in the same document that granted the extra year, and the sentence is easy to miss because it sits in the final paragraph: “The exemptions described in this notification are not intended to provide, and should not be viewed as providing, a justification for delaying efforts by small business dispensers to implement the enhanced drug distribution security requirements under section 582(g)(1) of the FD&C Act. FDA strongly urges small business dispensers to continue their efforts to implement necessary measures to satisfy these enhanced drug distribution security requirements to strengthen supply chain integrity and further protect public health.”

That is unusually pointed language for an exemption document, and it is more pointed for appearing in the second one rather than the first. It is also a fair description of the practical position: the data half depends on your wholesalers’ onboarding queues, which will not get shorter as the date approaches, and the written half depends on decisions only the pharmacy can make. We walk all six obligations one at a time with the FDA’s language attached to each.

Where DoseTrace fits

DoseTrace produces the written half only. We do not move, host or transmit transaction data, that stays between you and your wholesalers, and if your gap is the data side, a track-and-trace platform is the right purchase, not this one. What we prepare is the nine-document readiness binder: the exemption determination with the headcount behind it, the trading-partner verification log, the standard operating procedures, the tracing response runbook, the training attestation and the six-year retention plan, each one dated. It is $99 flat, one time, from a 15-minute intake, and we publish that beside everyone else’s price we could verify. If you would rather have someone else do it, six kinds of organisation prepare this documentation and we name them all.

Check which exemption track you are on, free, or contact us to reach a person.

Every statutory quotation on this page is from the FDA document DSCSA Exemptions from Certain Requirements Under Section 582 of the FD&C Act for Small Business Dispensers, issued 6 August 2026, the letter that now grants the small-dispenser exemption, retrieved and verified 11 August 2026. It supersedes the 12 July 2024 letter this page previously quoted, and FDA republished it at the same address, so that URL no longer returns the 2024 text. The reference to the weaker “recommend” wording is a comparison with the separate 9 October 2024 letter, which governs other trading partners and dispensers with 26 or more full-time employees. This page names no distributor because we quote only sources we have retrieved. DoseTrace is not a law firm and nothing here is legal advice.